thought post call still
plenti ga tank
trikafta robust plenti runway beyond
biopharma complet immun guidanc cut amidst covid-
pandem think vertex stand signific upsid
higher cf revenu guidanc midpoint even
fast start trikafta launch ytd out-performance
think vertex growth stori still earli stage beyond current adult
market increment cystic fibrosi cf patient ww basi
treatment option becom elig trikafta soon provid plenti growth runway
view inde would argu vertex multipl biotech peer still
ep peer long durat franchis limit competit
concern combin pipelin capabl produc high impact drug
capac willing remain aggress complementari asset
technolog give us confid long-term view reflect faster trikafta
uptak rais cf forecast increas po
reiter buy vertex list
tripl combo file patient age ema review decis
expect trikafta phase studi age fulli enrol file
expect model launch earli enrol phase studi
paus though studi still activ phase
studi sickl cell diseas beta-thalassemia track report addit data
new patient follow patient describ previous studi
schedul addit patient initi dose current
updat model quarter increas trikafta assumpt
forecast revenu
prior respect new non-gaap ep estim
respect wacc chang
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
vertex biopharmaceut compani focus
discoveri develop market new
therapi treatment cystic fibrosi
rate vertex buy differenti growth
profil compar peer compani potenti
upsid on-going trikafta launch
million
price object vertex base npv analysi
forecast sale approv product kalydeco orkambi symdeko
trikafta assum wacc line peer compani
similar size risk vari termin growth rate asset base
characterist patent life given assumpt estim
valu kalydeco orkambi symdeko
trikafta net cash pipelin
risk price object payer pushback price difficulti secur
reimburs agreement particularli eu clinic trial failur new
competitor cystic fibrosi
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
